Search Results for: CSNK2B

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel CIP2A cellular inhibitor of PP2A
Novel CRISP2 cysteine rich secretory protein 2
Novel GTPBP2 GTP binding protein 2
  • Platelet degranulation
Novel KCNA3 potassium voltage-gated channel subfamily A member 3
  • Voltage gated Potassium channels
  • Enflurane
  • Clofazimine
  • Promethazine
  • Miconazole
  • Dalfampridine
Novel TRIM27 tripartite motif containing 27
  • SUMOylation of ubiquitinylation proteins
  • Regulation of PTEN stability and activity
  • Suppression of apoptosis
Novel ZFP36L1 ZFP36 ring finger protein like 1
  • Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
Novel ZNF76 zinc finger protein 76
ABHD4 abhydrolase domain containing 4, N-acyl phospholipase B
  • Acyl chain remodelling of PE
ACTB actin beta
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Gap junction degradation
  • Formation of annular gap junctions
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • HATs acetylate histones
  • Prefoldin mediated transfer of substrate to CCT/TriC
  • Folding of actin by CCT/TriC
  • EPHB-mediated forward signaling
  • EPH-ephrin mediated repulsion of cells
  • Adherens junctions interactions
  • Adherens junctions interactions
  • Recycling pathway of L1
  • Recycling pathway of L1
  • VEGFA-VEGFR2 Pathway
  • Interaction between L1 and Ankyrins
  • Interaction between L1 and Ankyrins
  • Cell-extracellular matrix interactions
  • B-WICH complex positively regulates rRNA expression
  • RHO GTPases activate IQGAPs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Formins
  • MAP2K and MAPK activation
  • UCH proteinases
  • DNA Damage Recognition in GG-NER
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Clathrin-mediated endocytosis
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • Quercetin
  • Phenethyl Isothiocyanate
  • Other phagocyte defects, including the following eight diseases: Chediak-Higashi syndrome; Griscelli syndrome, type 1 (GS1); Griscelli syndrome, type 2 (GS2); Griscelli syndrome, type 3 (GS3); beta-actin deficiency; Neutrophil-specific granule deficiency; Myeloperoxidase deficiency; Glucose 6-phosphate dehydrogenase deficiency; Shwachman syndrome
ACTL6B actin like 6B
  • RMTs methylate histone arginines
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
ACTR1B actin related protein 1B
  • MHC class II antigen presentation
  • Neutrophil degranulation
ACTR5 actin related protein 5
  • UCH proteinases
  • DNA Damage Recognition in GG-NER
ACVRL1 activin A receptor like type 1
  • Signaling by BMP
  • ATP
  • Hereditary hemorrhagic telangiectasia (HHT)
ADD1 adducin 1
  • Caspase-mediated cleavage of cytoskeletal proteins
  • XBP1(S) activates chaperone genes
  • Miscellaneous transport and binding events
ADH5 alcohol dehydrogenase 5 (class III), chi polypeptide
  • Ethanol oxidation
  • NADH
  • Lauric acid
  • 12-Hydroxydodecanoic Acid
  • S-Hydroxymethyl Glutathione
ANGPT2 angiopoietin 2
  • Tie2 Signaling
  • Faricimab
ANKRD28 ankyrin repeat domain 28
  • Telomere Extension By Telomerase
  • COPII-mediated vesicle transport
AP2M1 adaptor related protein complex 2 subunit mu 1
  • Nef mediated downregulation of CD28 cell surface expression
  • Nef Mediated CD4 Down-regulation
  • Retrograde neurotrophin signalling
  • Retrograde neurotrophin signalling
  • Nef Mediated CD8 Down-regulation
  • Gap junction degradation
  • Formation of annular gap junctions
  • MHC class II antigen presentation
  • EPH-ephrin mediated repulsion of cells
  • Recycling pathway of L1
  • Recycling pathway of L1
  • WNT5A-dependent internalization of FZD4
  • WNT5A-dependent internalization of FZD2, FZD5 and ROR2
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • VLDLR internalisation and degradation
  • LDL clearance
  • Potential therapeutics for SARS
APLP1 amyloid beta precursor like protein 1
  • Zinc
  • Copper
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
ARAF A-Raf proto-oncogene, serine/threonine kinase
  • RAF activation
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by MRAS-complex mutants
  • ATP
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)

Page 1 out of 12 pages